Introduction of a new recombinant vaccine based on GRP78 for breast cancer immunotherapy and evaluation in a mouse model.

Introduction: Breast cancer is one of the most prevalent malignancies in women. Several treatment options are available today, including surgery, chemotherapy, and radiotherapy. Immunotherapy, as a highly specific therapy, involves adaptive immune responses and immunological memory. In our present research, we used the recombinant C-terminal domain of the GRP78 (glucose- regulated protein 78) protein to induce an immune response and investigate its therapeutic impact in the 4T1 breast cancer model. Methods: BALB/c mice were immunized with the cGRP78 protein. The humoral immune response was assessed by ELISA. Then, BALB/c mice were injected subcutaneously with 1×106 4T1 tumor cells. Subsequently, tumor size and survival rate measurements, MTT, and cytokine assays were performed. Results: The animals receiving the cGRP78 vaccine showed significantly more favorable survival and slower tumor growth rates compared with unvaccinated tumor-bearing mice as the negative control mice. Circulating levels of tumoricidal cytokines such as IFNγ were higher, whereas tolerogenic cytokines such as IL-2, 6, and 10 either did not increase or had a decreasing trend in mice receiving cGRP78. Conclusion: cGRP78 vaccines generated potent immunotherapeutic effects in a breast cancer mouse model. This novel strategy of targeting the GRP78 protein can promote the development of cancer vaccines and immunotherapies for breast cancer malignancies.

Health effects associated with long-term occupational exposure of employees of a chlor-alkali plant to mercury.

This study aimed to evaluate possible health effects associated with long-term occupational exposure to low levels of mercury vapors. Forty-six subjects exposed to mercury and 65 healthy unexposed employees were studied. The subjects were administered a questionnaire on experienced symptoms and underwent clinical examinations as well as routine biochemical tests. Atmospheric and urinary concentrations of mercury were measured, too. Environmental concentrations of mercury were estimated to be 3.97 ± 6.28 µg/m(3) and urinary concentrations of mercury in exposed and referent groups were 34.30 ± 26.77 and 10.15 ± 3.82 µg/dm(3), respectively. Additionally, symptoms such as somatic fatigue, anorexia, loss of memory, erethism, blurred vision and teeth problems were significantly more common among exposed individuals. These observations indicate that occupational exposure to mercury vapors, even at low levels, is likely to be associated with neurological and psychological symptoms.